Topics

TME Hinders CAR-T for Solid Tumors

CAR-T cells can eliminate large burdens of antigen-positive blood cancer, yet comparable success in solid tumors remains limited. The tumor microenvironment is a central reason for this difference. A solid lesion is not simply a collection of target cells: abnormal vessels, dense extracellular matrix, cancer-associated fibroblasts, suppressive myeloid cells, regulatory T cells, and metabolically stressed regions create successive barriers to entry and function. Tumor antigens are also heterogeneous and often shared with normal tissues, narrowing the therapeutic window. Early clinical studies have often demonstrated feasibility and occasional responses without the reproducible durability seen in B-cell malignancies. Contemporary research therefore treats CAR design, trafficking, and microenvironmental resistance as one integrated engineering problem rather than expecting a receptor optimized for leukemia to work unchanged in a solid mass[1][2][3].

CAR-T cells must first leave the circulation, adhere to tumor vasculature, follow an appropriate chemokine gradient, and penetrate matrix before reaching malignant cells. Once inside, hypoxia, acidity, nutrient depletion, adenosine, reactive oxygen species, and inhibitory cytokines such as TGF-β impair proliferation and cytotoxicity. PD-L1 and other checkpoint ligands reinforce exhaustion, while macrophages and myeloid-derived suppressor cells limit antigen presentation and T-cell survival. Repeated recognition of uneven antigen density can drive activation-induced dysfunction, whereas complete antigen loss permits escape. On-target recognition of low antigen levels in essential normal tissue can cause a different and potentially severe form of failure. These mechanisms are interdependent: poor perfusion creates metabolic stress, fibroblast-derived matrix restricts movement, and chronic signaling in the remaining accessible tumor further erodes CAR-T fitness[1][2].

Engineering strategies address different points in this obstacle course. Chemokine receptor expression can improve homing; regional or intratumoral delivery can shorten the trafficking route; heparanase or matrix-directed approaches can enhance penetration. Dominant-negative receptors, switch receptors, checkpoint disruption, and secretion of selected cytokines may resist local inhibition. Logic-gated, tandem, or multispecific CARs can better recognize heterogeneous tumors while controlling off-tumor activation. Combinations with checkpoint blockade, antiangiogenic therapy, oncolytic viruses, radiation, or myeloid-targeted agents may remodel the niche before or during cell therapy. Suicide switches and controllable receptor systems offer safeguards when added functions increase uncertainty. Each intervention adds biological potency but may also increase systemic inflammation, autonomous growth, or damage to normal tissues[1][3].

Progress requires models and trials that measure spatial biology rather than response alone. Tumor biopsies should determine whether failure reflects absent trafficking, inadequate antigen, metabolic collapse, or acquired dysfunction, because these mechanisms demand different solutions. Manufacturability and safety circuits must remain priorities as increasingly armored cells are developed. Serial imaging and circulating biomarkers can complement biopsy but should not substitute for direct evidence of intratumoral cell state. Trials should also document whether engineered cells reach separate metastatic sites. Comparative studies should establish when regional administration is superior, which microenvironmental biomarker predicts benefit from a combination, and whether transient programming can provide sufficient resistance with less long-term risk. Solid-tumor CAR-T therapy will advance through modular, mechanism-matched designs: a precise receptor is necessary, but it must be paired with the capacity to reach, survive within, and repeatedly function in a hostile tumor microenvironment[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Product Guides
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-10201 Sorafenib
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
316
HY-10231 PX-478
PX-478 is a multifunctional HIF-1α inhibitor with properties including radiosensitization, autophagy activation, and lipid accumulation inhibition. PX-478 also blocks hypoxia-induced VEGF production and regulates β-cell phenotypes under hypoxic conditions. PX-478 induces cell cycle arrest and DNA damage, restores autophagic function, reduces foam cell formation, and maintains glucose homeostasis. PX-478 is widely used in research on related diseases such as human tumors (e.g., prostate cancer), type 2 diabetes, and atherosclerosis.
115
HY-13013 SIS3
SIS3 is a potent and selective inhibitor of Smad3 with an IC50 of 3 μM for Smad3 phosphorylation. SIS3 inhibits the myofibroblast differentiation of fibroblasts by TGF-β1.
113
HY-10255A Sunitinib
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
113
HY-50912 Plerixafor octahydrochloride
Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.
112
HY-10046 Plerixafor
Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM.
112
HY-10981 Lenvatinib
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
104
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.
100
HY-10331 Regorafenib
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity.
96
HY-B0673 Pirfenidone
Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.
96
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
88
HY-L076 Drug-Induced Liver Injury (DILI) Compound Library
Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug. DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver. MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 641 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.
84
HY-L169 Anti-Drug-Resistant Compound Library
Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important. MCE designs a unique collection of 706 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.
83
HY-L172 Immunopotentiator Compound Library
Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines. MCE designs a unique collection of 150 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.
83
HY-L204 Lactic Acid Metabolic Compound Library
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism. MCE contains 582 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.
83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L234 Nucleotide Metabolite Compound Library
Nucleotide metabolism is central to cancer aggressiveness, underpinning uncontrolled proliferation, chemotherapy resistance, immune evasion, and metastasis. It is transcriptionally regulated by oncogenes (e.g., MYC) and tumor suppressors (e.g., pRb). Nucleotide imbalance and nucleoside degradation further regulate cell state transitions, especially following replication stress. Additionally, secretion of nucleotides/nucleosides into the tumor microenvironment modulates immune responses and influences treatment efficacy. Therefore, nucleotide metabolites have roles in disease response and indication in cancer research, and can be utilized to develop cancer-related mechanisms and drugs. MCE can provide 83 metabolites produced by nucleotide metabolic pathways, which can be used for disease mechanism research and drug research.
83
HY-L250 Lactic Acid Metabolite Compound Library
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies. The MCE lactic acid metabolite compound library contains 61 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.
83
HY-10374 Semaxinib
Semaxinib (SU5416) is a potent and selective inhibitor of VEGFR (Flk-1/KDR) with an IC50 of 1.23 μM.
81
HY-N0488A Vincristine
Vincristine (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas.
79
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
75
HY-50904 Nintedanib
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
75
HY-16711 SB225002
SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125I-IL-8 binding to CXCR2 with an IC50 of 22 nM.
66
HY-15251 Reparixin
Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.
65
HY-P9906 Bevacizumab
Bevacizumab (Anti-Human VEGF, Humanized Antibody) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab possesses immunomodulatory properties. Bevacizumab can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer.

Species: Human

63
HY-100347A SRI-011381 hydrochloride
SRI-011381 hydrochloride is an orally active TGF-β signaling agonist, exhibits neuroprotective effects, with blood-brain barrier permeability.
61
HY-100347 SRI-011381
SRI-011381 is an orally active TGF-β signaling agonist, exhibits neuroprotective effects.
61
HY-13016 Cabozantinib
Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.
59
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

42
HY-15319 AMG 487
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC50s of 8.0 and 8.2 nM, respectively.
40
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
34
HY-16268 Kartogenin
Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research.
33
HY-10198 Navarixin
Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly.
32
HY-K2005 High Sensitivity ECL Kit

High Sensitivity ECL Kit enables low picogram detection of antigen by oxidizing luminol in the presence of HRP and peroxide. This reaction produces a prolonged chemiluminescence which can be visualized on X-ray film or digital imaging systems. The 100 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

32
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

27
HY-13848 Rugocrixan
AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively.
26
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

23
HY-17389 Genipin
Genipin ((+)-Genipin) is a natural crosslinking reagent derived from Gardenia jasminoides Ellis fruits. Genipin inhibits UCP2 (uncoupling protein 2) in cells. Genipin has a variety of bioactivities, including modulation on proteins, antitumor, anti-inflammation, immunosuppression, antithrombosis, and protection of hippocampal neurons. Genipin also can be used for type 2 diabetes research.
22
HY-N1584 Halofuginone
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.
22
HY-A0181 Adenosine monophosphate
Adenosine monophosphate is an adenosine A1 receptor agonist. Adenosine monophosphate has significant antiviral activity against HSV-1 and HSV-2. Adenosine monophosphate is a key cellular metabolite regulating energy homeostasis and signal transduction.
22
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

20
HY-N0439 Asiaticoside
Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.
19
HY-19533 SCH 58261
SCH 58261 is a potent, selective and competitive antagonist of adenosine A2A receptor with an IC50 of 15 nM, and displays 323-, 53- and 100-fold more selective for A2A receptor than A1, A2B, and A3 receptors, respectively.
18
HY-Y0966 Glycine
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine inhibits the membrane aggregation of NINJ1 and prevents plasma membrane rupture during cell death. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis.
18
HY-10888 Istradefylline
Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.
16
HY-19532 ZM241385
ZM241385 is a potent, high affinity and selective adenosine A2a receptor (A2AR) antagonist with a Ki value of 1.4 nM.
16
HY-N0092 Inosine
Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors.
16
HY-13201A CGS 21680 Hydrochloride
CGS 21680 Hydrochloride is a selective adenosine A2A receptor agonist with a Ki of 27 nM.
14
HY-B0809 Theophylline
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research.
14
HY-13406 TAK-779
TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC50 and EC90 of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.
13
HY-116084 Trimethylamine N-oxide
Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway.

Source: Host intestinal bacteria

12
HY-19855 AZD-5069
AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.
11
HY-W074143 Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride
Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride ([Ru(dpp)3]2+) is an electrochemiluminescent (ECL) probe and oxygen-sensitive sensor. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride can be used to modify electrode surfaces for the detection of sulfates (S2O82-) and oxalates, based on electrochemical reactions that generate excited-state species, releasing photons through irreversible redox reactions. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride utilizes the oxygen quenching of fluorescence mechanism, where fluorescence intensity reflects the metabolic rate of living microorganisms or oxygen levels within cells/tumors, allowing for real-time detection. Tris(4,7-diphenyl-1,10-phenanthroline)ruthenium(II) dichloride's main applications include microbial detection, antibacterial activity studies, and tumor microenvironment research.
11
HY-100806 Kynurenic acid
Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.
11
HY-16938 5'-Methylthioadenosine
5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
10
HY-100937 DPCPX
DPCPX (PD 116948), a xanthine derivative, is a highly potent and selective Adenosine A1 receptor antagonist, with a Ki of 0.46 nM in 3H-CHA binding to A1 receptors in rat whole brain membranes.
9
HY-103173 5'-N-Ethylcarboxamidoadenosine
5'-N-Ethylcarboxamidoadenosine (NECA) is a nonselective adenosine receptor agonist.
8
HY-K2006 Sensitive ECL Kit

Sensitive ECL Kit enables low picogram detection of antigen by oxidizing luminol in the presence of HRP and peroxide. This reaction produces a prolonged chemiluminescence which can be visualized on X-ray film or digital imaging systems. The 100 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

8
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

7
HY-N0447 8-Gingerol
8-Gingerol can be found in the rhizome of ginger (Z. officinale) and has oral bioactivity. It activates TRPV1, with an EC50 value of 5.0 µM. 8-Gingerol inhibits COX-2 and also suppresses the growth of H. pylori in vitro. Additionally, 8-Gingerol exhibits anticancer, antioxidant, and anti-inflammatory properties by inhibiting the epidermal growth factor receptor (EGFR) and modulating its downstream STAT3/ERK pathway to suppress the proliferation, migration, and invasion of colorectal cancer cells. 8-Gingerol also exerts immunosuppressive effects by inhibiting oxidative stress, inducing cell cycle arrest, promoting apoptosis, and regulating autophagy. Furthermore, 8-Gingerol has cardioprotective effects. 8-Gingerol is promising for research in the fields of cancer, infection, immunosuppression, and cardiovascular diseases.
5
HY-32736 Triptonide
Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a Wnt signaling inhibitor with an IC50 of appropriately 0.3 nM. Triptonide has immunosuppression, anti-inflammatory, anti-fertility, neuroprotective and anti-lymphoma effects.
4
HY-B1180 Vinburnine
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
3
HY-W010936 Nitrobenzylthioinosine
Nitrobenzylthioinosine is an ENT1 transporter inhibitor that binds to ENT1 transporter with high affinity. Nitrobenzylthioinosine is a photoaffinity probe for adenosine uptake sites in brain. Nitrobenzylthioinosine can cross the blood-brain barrier.
3
HY-P99241 Ponsegromab
Ponsegromab is a Growth differentiation factor 15 (GDF15) inhibitor with human, cynomolgus monkey, and mouse target IC50 values of 0.123 nM, 0.053 nM, and 0.102 nM, respectively. Ponsegromab acts as a chemosensitizer, increases intracellular reactive oxygen species, reduces glutathione levels. Ponsegromab can be used for the research of oxaliplatin-resistant colorectal cancer.

Species: Human

3
HY-K0353 Human CD3/CD28 T Cell Activation Magnetic Beads

MCE Human CD3/CD28 T Cell Activation Magnetic Beads are based on the two important co-stimulatory signals, without relying on feeder cells (antigen-presenting cells) or antigens, CD3 and CD28, without relying on feeder cells (antigen-presenting cells) or antigens, enabling simple and rapid T cell activation.

3
HY-N6985 Baccatin III
Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment.
2
HY-W016562 Hippuric acid
Hippuric Acid is an orally active metabolite. Hippuric Acid can be produced by intestinal microorganisms from the metabolism of polyphenols, benzoic acid. Hippuric Acid decreases NRF2, MMP9 and leads to ROS accumulation. Hippuric Acid activates TGFβ/SMAD signaling. Hippuric Acid improves hyperuricemia and colitis. Hippuric Acid can also be used in cardiovascular disease research. .
2
HY-161541 Estradiol/BSA
Estradiol/BSA is the antigen-adjuvant conjugate formed by the coupling of Estradiol (HY-B0141) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
1
HY-P991451 Anti-ALPP Antibody
Anti-ALPP Antibody (SGN-ALPV antibody) is a human monoclonal antibody (mAb) targeting ALPP. Anti-ALPP Antibody can be used in solid tumors research.

Species: Human

1
HY-P5623B RVG TFA
RVG TFA is a peptide derived from Rabies Virus Glycoprotein that binds to the α-7 subunit of nicotinic acetylcholine receptors (AchR) of neuronal cells. RVG enhances delivery of Mycobacterium tuberculosis antigens to antigen-presenting cells.
1
HY-P99812 Ragifilimab
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab binds to and activates GITR on T cells, which stimulates the immune system to enhance its anti-tumor activity. Ragifilimab can be used for advanced or metastatic solid tumors research.

Species: Human

1
HY-D1833 Vari Fluor 680 TSA (200×)
Vari Fluor 680 TSA (200×) (VF 680 Tyramide) is a fluorescent probe belonging to the Vari Fluor TSA series. Vari Fluor TSA series fluorescent probes can be used for high-density in situ labeling of target antigens using horseradish peroxidase (HRP) assays, which are widely used in ELISA, IF, IHC and other techniques with high detection sensitivity.
1
HY-P3448 Certepetide
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
1
HY-16938S1 5'-Methylthioadenosine-d3
5'-Methylthioadenosine-d3 is the deuterium labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
1
HY-P9947 Efalizumab
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research.

Species: Human

1
HY-P99039 Oleclumab
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity.

Species: Human

1
HY-P99742 Mitazalimab
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.

Species: Human

1
HY-W591424 m-PEG2000-NHS ester
m-PEG2000-NHS ester (mPEG2000-SC) is a reagent with both cell adhesion inhibition and peptide conjugation functions. The NHS ester group of m-PEG2000-NHS ester forms stable amide bonds with primary amine-containing molecules (e.g., the N-terminus of MMP-2-cleavable octapeptide) to generate mPEG-peptide intermediates for liposome surface modification. When m-PEG2000-NHS ester is immobilized on a cystamine-modified gold surface, it can construct an in vitro model for cell adhesion kinetic studies, and higher PEG density and thicker layers correlate with lower cell adhesion rates. m-PEG2000-NHS ester can synthesize MMP-2-responsive PEGylated lipid conjugates to achieve MMP-triggered dePEGylation in the tumor microenvironment. m-PEG2000-NHS ester can be used in studies related to colon cancer and other conditions.
1
HY-N0819 Raddeanin A
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
1
HY-D1834 Vari Fluor 640 TSA (200×)
Vari Fluor 640 TSA (200×) (VF 640 Tyramide) is a fluorescent probe belonging to the Vari Fluor TSA series. Vari Fluor TSA series fluorescent probes can be used for high-density in situ labeling of target antigens using horseradish peroxidase (HRP) assays, which are widely used in ELISA, IF, IHC and other techniques with high detection sensitivity.
1
HY-P99044 Sabatolimab
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.

Species: Human

1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

1
HY-P72720 CD58 Protein, Human (HEK293, His)
CD58, a glycoprotein, is also known as lymphocyte-function antigen 3 (LFA-3). CD58 is a costimulatory receptor, and can interact with its natural ligand (CD2, primarily expressed on the surface of T/NK cells). The CD2-CD58 interaction can promote cell adhesion and recognition, and regulate antiviral responses, inflammatory responses in autoimmune diseases, immune rejection of transplantation, and immune evasion of tumor cells. CD58 Protein, Human (HEK293, His) is the recombinant human-derived CD58 protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

1
HY-K0221 Affinity Chromatography Column

MCE Affinity Chromatography (AC) Columns are designed for purification of recombinant proteins with different tags, enzymes, antibodies, antigens and nucleic acids.

1
HY-P990031 Dargistotug
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function.

Species: Human

/
HY-W725543 Chlorphenesin-d5
Chlorphenesin-d5 is the deuterium labeled Chlorphenesin (HY-A0133). Chlorphenesin is a reversible antigen-associated immunosuppressant. Chlorphenesin is an antibacterial and antifungal agent used in numerous eye care cosmetics.
/
HY-156087G Cholicamideβ (GMP)
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis.
/
HY-P5351 Hyaluronan-binding peptide, biotin labeled
Hyaluronan-binding peptide, biotin labeled is a biological active peptide. (This peptide is a hyaluronan-binding peptide biotinylated through a C-terminal GGGSK linker. Hyaluronan (HA) is a nonsulfated glycosaminoglycan expressed in the extracellular matrix and on cell surfaces. HA plays a role in fertilization, embryonic development, wound healing, angiogenesis, leukocyte trafficking to inflamed tissues, and cancer metastasis. This peptide has been shown to block HA binding to CD44 receptors and inhibit T cell proliferation.)
Others  
Cancer  
/
HY-W747965 8-Bromoguanosine-13C2,15N
8-Bromoguanosine-13C2,15N is the 13C- and 15N-labeled 8-Bromoguanosine (HY-W019033). 8-Bromoguanosine is a purine nucleoside, a brominated derivative of guanosine. 8-Bromoguanosine can reduce the conformational heterogeneity of RNA to enhance its function.
/
HY-P11152 HIV-1 tat Protein (1-9)
HIV-1 tat Protein (1-9) occurs extracellularly and has a role in the immunosuppression of non-HIV-1-infected T cells in acquired AIDS. HIV-1 tat Protein (1-9) is an inhibitor of DP IV. HIV-1 tat Protein (1-9) can be synthesized by phase peptide synthesis with Fmoc (N-(9-fluorenyl)methoxycarbonyl) technique using the peptide synthesizer 431A. HIV-1 tat Protein (1-9) can be studied in research on HIV-1.
/
HY-109506S6 DPPC-d66
DPPC-d66 is deuterium labeled DPPC. DPPC (129Y83) is a zwitterionic phosphoglyceride that can be used for the preparation of liposomal monolayers. DPPC-liposome serves effectively as a delivery vehicle for inducing immune responses against GSL antigen in
/
HY-P99723 Manelimab
Manelimab (BCD-135) is a monoclonal antibody targeting PD-L1 with PD-L1 inhibitory activity. Manelimab blocks the interaction between PD-L1 and PD-1 to abrogate the immunosuppressive signals of T cells in the tumor microenvironment. Manelimab is applicable for tumor-related research.

Species: Human

Cancer  
/
HY-N12331 Ohchinolide B
Ohchinolide B is a tubulin inhibitor. Ohchinolide B inhibits microtubule polymerization (IC50=2.3 μM) and induces G2/M phase cell cycle arrest via mitochondrial apoptotic pathways. Ohchinolide B is promising for research of solid tumors (e.g., breast, lung cancer).
/
HY-109506S8 DPPC-d75
DPPC-d75 is deuterium labeled DPPC. DPPC (129Y83) is a zwitterionic phosphoglyceride that can be used for the preparation of liposomal monolayers. DPPC-liposome serves effectively as a delivery vehicle for inducing immune responses against GSL antigen in
/
HY-P3640 MAGE-3 Antigen (167-176) (human)
MAGE-3 Antigen (167-176) (human) is a polypeptide containing eight amino acids. MAGE-3 Antigen (167-176) (human) is a human leukocyte antigen HLA-B44 molecules epitope encoded by melanoma antigen gene (MAGE).
Others  
Cancer  
/
HY-16938R 5'-Methylthioadenosine (Standard)
5'-Methylthioadenosine (Standard) is the analytical standard of 5'-Methylthioadenosine. This product is intended for research and analytical applications. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].
/
HY-N16004 C18:0 B Antigen ceramide (d18:1/18:0)
C18:0 B Antigen ceramide (d18:1/18:0) is a ganglioside.
/
HY-N1480S2 (-)-Fucose-13C-2
(-)-Fucose-13C-2 is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti[
/
HY-P4088 LyP-2
LyP-2 is a peptide that homes to tumor lymphatics. LyP2 homes to lymphatics of C8161 melanomas and cervical carcinomas and K14-HPV16 skin, but not to MDA-MB435 tumors, showing heterogeneity in the molecular markers of tumor cells and lymphatics.
Others  
Cancer  
/
HY-N20499 Pulsatillae extract
Pulsatilla extract is an extract of Pulsatilla chinensis that reduces tumorigenesis, metastasis, and immunosuppression by blocking the MAPK signaling pathway.
p38 MAPK  
Cancer  
/
HY-158279 Gentamicin/OVA
Gentamicin/OVA is an antigen-adjuvant conjugate conjugate of Gentamicin (HY-A0276A) and ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the production of antigen-specific T cells.
/
HY-W767371 8-Bromoguanosine-13C,15N2
8-Bromoguanosine-13C,15N2 is the 13C- and 15N-labeled 8-Bromoguanosine (HY-W019033). 8-Bromoguanosine is a purine nucleoside, a brominated derivative of guanosine. 8-Bromoguanosine can reduce the conformational heterogeneity of RNA to enhance its function.
/
HY-P10950 PD-L1 inhibitory peptide
PD-L1 inhibitory peptide is an inhibitor peptide targeting programmed cell death ligand 1 (PD-L1). PD-L1 inhibitory peptide binds to PD-L1, relieving immunosuppression and restoring the antitumor activity of T cells. PD-L1 inhibitory peptide is promising for research of cancers.
/
HY-N9382 Gnidimacrin
Gnidimacrin is a protein kinase C (PKC) activator. Gnidimacrin inhibits cell growth of human leukemias, stomach cancers and non-small cell lung cancers in vitro, and shows activity against murine leukemias and solid tumors in vivo. Gnidimacrin can be used for leukemias, stomach cancers and non-small cell lung cancers research.
/
HY-161583 Marijuana/BSA
Marijuana/BSA is the antigen-adjuvant conjugate of Marijuana and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
/
HY-N0488S2 Vincristine-d6 sulfate
Vincristine-d6 (sulfate) is the deuterium labeled Vincristine sulfate. Vincristine sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas.
/
HY-D3391 RMR-Tre
RMR-Tre is a fluorescent probe targeting the mycobacterial acyltransferase Ag85. Under the catalysis of Ag85, RMR-Tre undergoes 6-position mycoloylation and anchors to the mycobacterial membrane, while achieving fluorescence activation by inhibiting the intramolecular twisted charge transfer state transition. RMR-Tre can distinguish live mycobacteria from dead ones through metabolism-driven labeling, enabling rapid, wash-free, low-background detection of viable bacteria. RMR-Tre reports the drug resistance of Mycobacterium tuberculosis via the trehalose catalytic shift activity readout associated with TreS. In addition, RMR-Tre can be combined with flow cytometry or high-content imaging techniques to visualize and quantitatively analyze the metabolic heterogeneity of Mycobacterium tuberculosis related to persistence and drug resistance. RMR-Tre is widely used in tuberculosis-related research.
/
HY-P2251 T-peptide
T-peptide, a Tuftsin analog, can be used for the research of human immunodeficiency virus (HIV) infection. T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. T-peptide also can inhibit the growth of residual tumor cells after surgical resection.
/
HY-N15985 BbGL-2
BbGL-2 is a glycosylated diacyl glycerol. BbGL-2 is an antigenic and is considered a candidate vaccine for Lyme disease.

Source: Borrelia burgdorferi

/
HY-P11597 Getacatetide
Getacatetide (CY-101) is a peptide-based Wnt/β-catenin inhibitor, which can be used for the study of solid tumors.
Wnt   β-catenin  
Cancer  
/
HY-167819 D-Erythro-sphingosyl phosphoinositol
D-Erythro-sphingosyl phosphoinositol is a lipid nanoparticle covalently linked to an antibody with potential activity in targeted compound delivery. D-Erythro-sphingosyl phosphoinositol can enhance the accumulation of compounds in specific cell types. D-Erythro-sphingosyl phosphoinositol may be used as a ligand to enhance the effect of antibodies in immunosuppression. D-Erythro-sphingosyl phosphoinositol can also be used to study the mechanisms related to cell signaling and lipid metabolism.
/
HY-130789 Cimigenol-3-one
Cimigenol-3-one inhibits Epstein-Barr virus early antigen (EBV-EA) activation.
EBV  
Infection  
/
HY-P9942 Sulesomab
Sulesomab (IMMU-MN3) is a murine monoclonal antibody fragment of the IgG1 class that binds to Normal Cross-Reactive Antigen-90 present on leukocytes. Sulesomab is cleared into infection nonspecifically through increased capillary membrane permeability.

Species: Human

/
HY-32736R Triptonide (Standard)
Triptonide (Standard) is the analytical standard of Triptonide. This product is intended for research and analytical applications. Triptonide (NSC 165677) is a natural product identified in Tripterygium wilfordii Hook F.. Triptonide is a Wnt signaling inhibitor with an IC50 of appropriately 0.3 nM. Triptonide has immunosuppression, anti-inflammatory, anti-fertility, neuroprotective and anti-lymphoma effects.
/
HY-W251598I Sodium bicarbonate, meets analytical specification of Ph. Eur., BP, USP, FCC, E500
Sodium bicarbonate, meets analytical specification of Ph. Eur., BP, USP, FCC, E500 is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
/
HY-N3065 Pierreione B
Pierreione B is a pyranoisoflavone, that can be isolated from the leaves and twigs of Antheroporum pierrei. Pierreione B demonstrates solid tumor selectivity with minimal cytotoxicity.
Others  
/
HY-N21911 Grandinin
Grandinin is a naturally occurring C-glucosidic ellagitannin with antitumor and anti-HSV activities. Grandinin exhibits selective cytotoxicity against human solid tumor cells. Grandinin inhibits the replication of HSV-1 and HSV-2 in Acyclovir (HY-17422)-resistant strains. Grandinin is used in research on melanoma and herpes simplex virus infection.
HSV  
/
HY-153209G Adjuvant-4 (GMP)
Adjuvant-4 (GMP) is a GMP grade Adjuvant-4. Adjuvant-4 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses. Adjuvant is generally an oil-in-water emulsifier of mineral oil and mannitol monooleate.
/
HY-16938S2 5'-Methylthioadenosine-13C5
5'-Methylthioadenosine-13C5 (5'-(Methylthio)-5'-deoxyadenosine-13C5) is the 13C--labeled 5'-Methylthioadenosine (HY-16938). 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
/
HY-P990038 Eurestobart
Eurestobart (ES002023) is a recombinant human IgG1 antibody against CD39. Eurestobart restores antitumor immunity by stabilizing the pro-inflammatory extracellular ATP (eATP) and interfering with synthesis of the immunosuppressive adenosine within the tumor microenvironment (TME). Eurestobart is used in the research of locally advanced and metastatic solid tumors.

Species: Human

/
HY-P992275 Anti-Nicastrin Antibody (A5226A)
Anti-Nicastrin Antibody (A5226A) is a monoclonal antibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease.

Species: Human

/
HY-P11798 P-Selectin binding peptide
P‑Selectin binding peptide is a short peptide that specifically targets P‑selectin. P‑Selectin binding peptide binds with high affinity to P‑selectin, which is highly expressed on activated platelets, inflamed endothelium, and in the tumor microenvironment. P‑Selectin binding peptide is used for precise targeted delivery and intervention in inflammation, thrombosis, and tumors.
/
HY-13582S1 Carbendazimb-d3
Carbendazimb-d3 is the deuterium labeled Carbendazimb (HY-13582). Carbendazim is a potent and orally active broad-spectrum?benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria,?Fusarium?and?Sclerotina. Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma.
/
HY-P991307 BND-35
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model.

Species: Human

/
HY-N20707 Castalagin
Castalagin is an orally active natural product with multiple biological activities including antibacterial activity against bacteria and anti-leishmanial activity against Leishmania aethiopica. Castalagin exhibits inhibitory activity against PARP1 and DNA topoisomerase II, with an IC50 of 0.86 μM for bovine PARP1. Castalagin reduces poly (ADP-ribosyl) ation modification in cells. Castalagin binds to the cell envelope of Ruminococcus bromii, increases the ratio of CD8+/FOXP3+CD4+ T cells in the tumor microenvironment, and acts as a prebiotic to enhance the activity of anti-PD-1 therapy. Castalagin induces morphological changes in Leishmania aethiopica promastigotes and inhibits their proliferation. Castalagin inhibits PBP2a-mediated peptidoglycan layer stabilization, disrupts bacterial peptidoglycan assembly, and inhibits and disintegrates bacterial biofilms. Castalagin can be used in research related to diseases such as cancer, leishmaniasis, and bacterial infections.
/
HY-101112 Okicenone
Okicenone is a Hu protein R (HuR) inhibitor. Okicenone inhibits HuR oligomerization, interferes with HuR RNA binding, HuR trafficking, cytokine expression and T-cell activation.

Source: Streptomyces

/
HY-N10510 Blood group A antigen tetraose type 5
Blood group A antigen tetraose type 5 (A-Tetrasaccharide) is a tetrasaccharide and a blood group specific oligosaccharide, inhibits the binding of anti-A antibody to blood group A substance. Blood group A antigen tetraose type 5 can be isolated from polar bear milk samples.

Source: polar bear

Others  
/
HY-P11129 MAGE-A4 (286-294)
MAGE-A4 (286-294) is a polypeptide derived from the 286th to 294th amino acids of the MAGE-A4 protein. MAGE-A4 (286-294) binds HLA-­A*02 with an affinity of 560.08 nM and an IC50 of 8.52 nM. MAGE-A4 (286-294) can be detected in various types of cancers (such as esophageal cancer, lung squamous cell carcinoma, bladder cancer). MAGE-A4 (286-294) can be used to produce CAR-T cells and to develop CAR-T cell therapy.
Others  
Cancer  
/
HY-105529 Indicine N-oxide
Indicine N-oxide (NSC 132319), a pyrrolizidine alkaloid, is an antitumor agent for pediatric cancer and solid tumors research.
/
HY-W753201 5'-Methylthioadenosine-13C
5'-Methylthioadenosine-13C (5'-(Methylthio)-5'-deoxyadenosine-13C) is the 13C-labeled 5'-Methylthioadenosine (HY-16938). 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
/
HY-P1842 MAGE-A3 (195-203)
MAGE-A3 (195-203) is a human leukocyte antigen (HLA) -A24 molecules epitope encoded by melanoma antigen gene (MAGE).
Others  
Cancer  
/
HY-N3887 Evoxine
Evoxine (Haplophytin B) is a compound that selectively inhibits CO2-induced immunosuppression and has activity in inhibiting the expression of interleukin-6 and chemokine CCL2 in human THP-1 macrophages. Evoxine shows antimicrobial activity against a wide range of bacteria, especially performing well in minimum inhibitory concentration (MIC) tests against Escherichia coli, Bacillus subtilis, and Staphylococcus aureus. Evoxine extracts may find application in crude drug preparations in West Africa, provided that their in vivo toxicity results are negative.
/
HY-159771 FAP6-19
FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
FAP  
Cancer  
/
HY-N15882 16:0 DNP Cap PE monoammonium
16:0 DNP Cap PE monoammonium is an antigenic lipid that plays a role in promoting antigen presentation on lipid bilayers.
/
HY-P11314 ABri
ABri, 34 amino acids long, is an Amyloid subunit with certain degree of N- and C-terminal heterogeneity and no sequence identity to any known amyloid protein. ABri is devoid of glycine, methionine, proline, aspartic acid, tryptophane, tyrosine and glutamine, featuring pyroglutamate at its N-terminus. ABri can be used for cerebral hemorrhages, ischemic infarction and Alzheimer disease research.
/
HY-W251598J Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard
Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is an inorganic salt. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is widely used in the fields of food, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate, United States Pharmacopeia (USP) Reference Standard is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
/
HY-P11089 TP53 neoepitope
TP53 neoepitope is a high-affinity antigenic peptide targeting HLA-A. TP53 neoepitope can triggers CD8+ T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .
MHC  
/
HY-N1480S1 (-)-Fucose-13C-1
(-)-Fucose-13C-1 is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti[
/
HY-P991903 PSB102
PSB102 is a humanized Fc-enhanced IgG1 monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20.

Species: Human

CD20  
Cancer  
/
HY-42360G SMCC (GMP)
SMCC (GMP) is the GMP level of SMCC (HY-42360). GMP guidelines are used to produce SMCC (HY-42360) (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. SMCC (GMP) is a protein crosslinker. SMCC (GMP) contains an amine-reactive N-hydroxysuccinimide ester and a sulfhydryl-reactive maleimide group that can be used in the conjugation of proteins. SMCC-conjugated antigen coupled spleen cells to induce antigen-specific immune responses.
/
HY-109506S5 DPPC-d13
DPPC-d13 is deuterium labeled DPPC. DPPC (129Y83) is a zwitterionic phosphoglyceride that can be used for the preparation of liposomal monolayers. DPPC-liposome serves effectively as a delivery vehicle for inducing immune responses against GSL antigen in
/
HY-W009538S 5'-Deoxy-5-fluorocytidine-d3
5'-Deoxy-5-fluorocytidine-d3 is deuterated labeled 5'-Deoxy-5-fluorocytidine (HY-W009538). 5'-Deoxy-5-fluorocytidine (5-Fluoro-5'-deoxycytidine) is a cytidine analog and metabolite of Capecitabine (HY-B0016). 5'-Deoxy-5-fluorocytidine is converted from Capecitabine by carboxylesterase in the liver. 5'-Deoxy-5-fluorocytidine is deaminated by cytidine deaminase to generate 5'-deoxy-5-fluorouridine, which is finally converted into 5-fluorouracil (HY-90006) by thymidine phosphorylase in tumor tissues to exert anti-tumor effects. 5'-Deoxy-5-fluorocytidine is used in the researches for solid tumors such as colorectal cancer, non-small cell lung cancer and breast cancer.
/
HY-P10507 MART-1 nonamer antigen
MART-1 nonamer antigen (LAGIGILTV) is a melanoma antigen that can be recognized by T cells. MART-1 nonamer antigen behaves as a superagonist by in vitro inducing specific T cells with enhanced immunological functions. MART-1 nonamer antigen can be used as a model to design peptides for use in anti-tumour vaccines.
Others  
Cancer  
/
HY-P11462 UNO peptide
UNO peptide is a MRC1-expressing TAMs (MEMs)-targeting peptide. UNO peptide targets CD206 on MEMs across a spectrum of solid tumors. UNO peptide can be used in the research of MEMs in breast cancer.
/
HY-169232 PCC16 chloride
PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers.
Cancer  
/
HY-N12105 Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside
Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is an anti-hepatitis B virus (anti-HBV) agent. Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside inhibits HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) secretion on Hep G2.2.15 cell line, with IC50 values of 1.67 and >2.15 mM, respectively.
HBV  
Infection  
/
HY-P991309 ZM-008
ZM-008 is an anti-LLT1 monoclonal antibody. ZM-008 blocks the interaction between LLT1 and CD161 on the surface of NK cells and T cells. ZM-008 restores anti-tumor immune activity, shifts the tumor microenvironment to an immune-responsive state, and recovers NK cell-mediated cytotoxicity against tumor cells, thereby reversing immunosuppression in immune-resistant "cold" tumors. ZM-008 is applicable to the research of immune-resistant solid tumors.

Species: Human

/
HY-P990174 Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32)
Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is an anti-mouse Pan-endothelial Cell Antigen/MECA-32 IgG2a monoclonal antibody. Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) can label endothelial cells. Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is often used for immunohistochemistry, delivery of siRNA and immunofluorescence.

Species: Mouse

Others  
/
HY-P3448S Certepetide-13C6,15N2
Certepetide-13C6,15N2 (CEND-1-13C6,15N2) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
/
HY-B1180R Vinburnine (Standard)
Vinburnine ((-)-Eburnamonine; (-)-Vincamone) (Standard) is the analytical standard of Vinburnine (HY-B1180). This product is intended for research and analytical applications. Vinburnine ((-)-Eburnamonine; (-)-Vincamone) phosphate is an orally active, blood-brain barrier permeable immunomodulator and apoptosis inducer. Vinburnine drives the secretion of IL-24 by activating the P38/MAPK/ATF3 signaling axis. Vinburnine induces reactive oxygen species production and DNA damage in cancer cells, thereby inhibiting cancer cell proliferation, activating the apoptotic cascade, and enhancing CD8+ T cell function to remodel the tumor immune microenvironment. Vinburnine can be used in the research of diseases such as melanoma.
/
HY-N0594R Deacetylasperulosidic Acid (Standard)
Deacetylasperulosidic Acid (Standard) is the analytical standard of Deacetylasperulosidic Acid. This product is intended for research and analytical applications. Deacetylasperulosidic Acid is an orally active antioxidant. Deacetylasperulosidic Acid exerts a definite in vivo antioxidant effect and alleviates oxidative stress injury by enhancing SOD activity. In atopic dermatitis models, Deacetylasperulosidic Acid corrects Th2-skewed immune imbalance and reduces allergy-related factors; in immunosuppression models, it activates cellular immunity, enhances NK cell activity and IL-2 production. Deacetylasperulosidic Acid can be used in the research of atopic dermatitis.
/
HY-172820 Trastuzumab envedotin
Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer.
/
HY-P3448S1 Certepetide-13C2,15N
Certepetide-13C2,15N (CEND-1-13C2,15N) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
/
HY-N15006 14-O-Acetylindolactam V
14-O-Acetylindolactam V can induce early Epstein-Barr virus antigen.
EBV  
Infection  
/
HY-N10024 Ganolactone
Ganolactone is a triterpenoid compound. Ganolactone has a weak inhibitory effect on EBV early antigen.
EBV  
Infection  
/
HY-159846S Luvometinib-d
Luvometinib-d (FCN-159-d) is the deuterated-labeled Luvometinib (HY-159846). Luvometinib is an orally potent MEK1/2 inhibitor. Luvometinib selectively blocks the MAPK signaling pathway by forming a ternary complex with MEKase and ATP, thereby reducing the phosphorylation level of ERK. Luvometinib induces cell cycle arrest and apoptosis, and inhibits cancer cell proliferation. Luvometinib can be used in relevant research on various solid tumors including melanoma, non-small cell lung cancer, colon cancer, and acute myeloid leukemia.
/
HY-P9994 Pertuzumab zuvotolimod
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research.
/
HY-N0488S1 Vincristine-d3-1 sulfate
Vincristine-d3 sulfate is the deuterium labeled Vincristine sulfate. Vincristine-1 sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine-1 sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine-1 sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine-1 sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas.
/
HY-N2274 23-Hydroxylongispinogenin
23-Hydroxylongispinogenin (12-Oleanene-3β,16β,23,28-tetrol) is extracted from Lysimachia heterogenea Klatt. Lysimachia heterogenea Klatt is a perennial herb, which is used as a folk medicine in subduing swelling and detoxicating in China. The effective fraction LH-1 of L. heterogene has antitumor activity.
Others  
Cancer  
/
HY-P4111A Peptide R TFA
Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. Peptide R (TFA) shows outstanding capacities to remodel the tumor stroma. Peptide R (TFA) can be used for solid tumor (glioblastoma, etc.) research.
CXCR  
/
HY-106801 Girolline
Girolline (RP 49532) is a protein synthesis inhibitor and a functional modulator of eIF5A. Girolline induces ribosome stalling by interfering with the binding of eIF5A to ribosomes. Girolline also inhibits the production of IL-6 and IL-8, and induces cell cycle arrest in tumor cells. Girolline is applicable to research related to inflammatory diseases, solid tumors, leukemia and malaria.

Source: Cymbastela cantharella (Pseudaxinyssa cantharella)

/
HY-P11742 WALP23
WALP23 is a synthetic model peptide. WALP23 induces heterogeneity in lipid bilayers, forming stripe-like microdomains in DPPC bilayers. WALP23 can be used to study protein-membrane interactions. WALP23 is also used as a model peptide to determine helical orientation during the association process.
/
HY-D1056B2 Lipopolysaccharides, from Proteus mirabilis
Lipopolysaccharides, from Proteus mirabilis are lipopolysaccharide endotoxins and TLR-4 activators derived from Proteus mirabilis, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from Proteus mirabilis exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Proteus mirabilis is a major pathogen causing urinary tract infections and may also contribute to rheumatoid arthritis. Lipopolysaccharides, from Proteus mirabilis also exhibit potential anti-tumor effects, demonstrating in vivo inhibitory activity against solid tumors such as meningosarcoma and Walker carcinosarcoma.
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.
/
HY-P4155 SSA antigenic peptide TFA
SSA antigenic peptide is an antigenic peptide of Sjögren's syndrome-related antigen A (SSA). SSA antigenic peptide can be used for the research of systemic lupus erythematosus.
/
HY-161552 T3/BSA
T3/BSA is an antigen-adjuvant conjugate of T3 (thyroid hormone) and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
/
HY-P4116A pH-Low Insertion Peptide TFA
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors.
/
HY-161526 T3/KLH
T3/KLH is an antigen-adjuvant conjugate formed by the coupling of T3 (thyroid hormone) with keyhole limpet hemocyanin (KLH). By coupling the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
/
HY-109506S7 DPPC-d71
DPPC-d71 is deuterium labeled DPPC. DPPC (129Y83) is a zwitterionic phosphoglyceride that can be used for the preparation of liposomal monolayers. DPPC-liposome serves effectively as a delivery vehicle for inducing immune responses against GSL antigen in
/
HY-161549 Phosphotyrosine/BSA
Phosphotyrosine/BSA is an antigen-adjuvant conjugate formed by coupling Phosphotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
/
HY-N1480S (-)-Fucose-13C
(-)-Fucose-13C is the 13C labeled (-)-Fucose. (-)-Fucose is classified as a member of the hexoses, plays a role in A and B blood group antigen substructure determination, selectin-mediated leukocyte-endothelial adhesion, and host-microbe interacti
/
HY-D2396 Sulfo SMCC R-phycoerythrin
Sulfo SMCC R-phycoerythrin is a conjugate composed of the protein crosslinker SMCC (HY-42360) and R-PE (R-Phycoerythrin) (HY-D0988) that can be used to label proteins to make them carry red fluorescence. Among them, SMCC is able to engage antigen-coupled spleen cells to induce antigen-specific immune responses.
/
HY-161566 DHT/BSA
DHT/BSA is an antigen-adjuvant conjugate formed by the coupling of DHT (dihydrotestosterone) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
/
HY-W654139 5'-Deoxy-5'-(methylthio)adenosine-d3
5'-Deoxy-5'-(methylthio)adenosine-d3 is deuterium labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
/
HY-N0488S Vincristine-d3 sulfate
Vincristine-d3 sulfate is the deuterium labeled Vincristine sulfate. Vincristine sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas.
/
HY-P99852 Dilpacimab
Dilpacimab (ABT165) is a bispecific variable domain immunoglobulin. Dilpacimab binds to and inhibits DLL4 and VEGF and acts as a tumor growth inhibitor. Dilpacimab can be used in research related to metastatic colorectal cancer and advanced solid tumors.

Species: Human

/
HY-P11097 Pep-20
Pep-20 is a CD47 binder with a human Kd of 2.91 µM and a murine Kd of 3.63 µM. Pep-20 blocks the interaction between CD47 and SIRPα, with an IC50 of 24.56 µM for human targets and 12.03 µM for murine targets. Pep-20 also acts as a phagocytosis enhancer and an inducer of anti-tumor immune responses. By blocking the CD47/SIRPα interaction, Pep-20 reduces the tyrosine phosphorylation level of SIRPα, disrupts the inhibitory "don't eat me" signaling pathway, enhances macrophage-mediated phagocytosis of solid tumor cells and hematologic tumor cells, and promotes macrophage mobilization of anti-tumor T-cell responses. Pep-20 can be used in research related to solid tumors, hematologic malignancies, breast cancer, and pancreatic cancer.
/
HY-P990056 Oberotatug
Oberotatug is a human IgG1κ antibody targeting the lymphocyte antigen LY75.

Species: Human

/
HY-16938S 5'-Methylthioadenosine-13C6
5'-Methylthioadenosine-13C6 is the 13C-labeled 5'-Methylthioadenosine. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis.
/
HY-N8389 Globulol
Globulol is a terpenoid metabolite and Antimicrobial agent. Globulol can be isolated from Alpinia oxyphylla Miq. Globulol binds to PAK4, reduces the expression level of PAK4 in cancer cells, decreases the phosphorylation of AKT, and downregulates the expressions of STAT3, phosphorylated STAT3, and PD-L1. Globulol promotes the secretion of CCL4 by cancer cells. Globulol reduces the viability and proliferation ability of cancer cells, induces G0/G1 cell cycle arrest and Apoptosis in cancer cells, and inhibits cancer cell migration and the integrity of 3D tumor spheres. Globulol enhances the relevant effects of anti-PD-1 agents in the cancer cell microenvironment. Globulol exhibits anticancer activity against liver cancer. Globulol inhibits the mycelial growth of phytopathogenic fungi and the growth of phytopathogenic bacteria. Globulol can be used in studies related to hepatocellular carcinoma.
/
HY-176785S MCB-294
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
Ras   Apoptosis   p38 MAPK   Caspase   TNF Receptor  
/
HY-13582S Carbendazim-d4
Carbendazim-d4 is the deuterium labeled Carbendazim. Carbendazim is a potent and orally active broad-spectrum?benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria,?Fusarium?and?Sclerotina. Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma.
/
HY-161560 Tacrolimus/BSA
Tacrolimus/BSA is the antigen-adjuvant conjugate formed by the conjugation of Tacrolimus (HY-13756) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
/
HY-P9957 Raxibacumab
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research.

Species: Human

/
HY-N14001 Naamidine J
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors.

Source: Pericharax heteroraphis

/
HY-P990704 Rilvegostomig
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.

Species: Human

/
HY-N3387 Licoricidin
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC50=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer. Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect. Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo. Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations.
/
HY-113008AS cis-Urocanic acid-13C3
cis-Urocanic acid-13C3 is the 13C-labeled cis-Urocanic acid. cis-Urocanic acid is a 5-HT2A receptor agonist. cis-Urocanic acid binds to 5-HT receptor with relatively high affinity (Kd=4.6 nM). cis-Urocanic acid is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.
/
HY-P10449 M2 Peptide
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis.
/
HY-N2732 6-Prenylapigenin
6-Prenylapigenin (6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin) is a prenylated flavonoid that exists in the stems and leaves of Maclura pomifera. 6-Prenylapigenin exhibits cytotoxicity against cancer cells such as leukemia cells and solid tumor cells.
Others  
Cancer  
/
HY-P0310 SV40 large T antigen NLS
SV40 large T antigen NLS is from Large T antigen residue 47 to 55, enables protein import into cell nucleus.
Others  
Infection  
/
HY-17389R Genipin (Standard)
Genipin (Standard) is the analytical standard of Genipin. This product is intended for research and analytical applications. Genipin ((+)-Genipin) is a natural crosslinking reagent derived from Gardenia jasminoides Ellis fruits. Genipin inhibits UCP2 (uncoupling protein 2) in cells. Genipin has a variety of bioactivities, including modulation on proteins, antitumor, anti-inflammation, immunosuppression, antithrombosis, and protection of hippocampal neurons. Genipin also can be used for type 2 diabetes research.
/
HY-P991364 Aldastotug
Aldastotug (PYX-106; BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

/
HY-161533 Digoxin/BSA
Digoxin/BSA is an antigen-adjuvant conjugate of Digoxin (HY-B1049) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
/
HY-128995AS Glycyl-Exatecan-d5 hydrochloride
Glycyl-Exatecan-d5 (Glycyl-DX-8951-d5) hydrochloride is deuterium labeled Glycyl-Exatecan (HY-128995A). Glycyl-Exatecan (Glycyl-DX-8951), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan has significantly antitumor activity. Glycyl-Exatecan can be used for cancers like solid tumors research.
/
HY-P99968 Clivatuzumab
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers.

Species: Human

Mucin  
Cancer  
/
HY-P991490 ISB2001
ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma.

Species: Human

CD38   CD3   TNF Receptor  
Cancer  
/
HY-D1832 Vari Fluor 532 TSA (200×)
Vari Fluor 532 TSA (200×) (VF 532 Tyramide) is a fluorescent probe belonging to the Vari Fluor TSA series. Vari Fluor TSA series fluorescent probes can be used for high-density in situ labeling of target antigens using horseradish peroxidase (HRP) assays, which are widely used in ELISA, IF, IHC and other techniques with high detection sensitivity.
/
HY-P99624 Foravirumab
Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III.

Species: Virus

RABV  
Infection  
/
HY-122094 Steppogenin
Steppogenin is a potent inhibitor of HIF-1α and DLL4, with IC50 values of 0.56 and 8.46 μM, respectively. Steppogenin can be sued for the research of angiogenic diseases, such as those involving solid tumors.
/
HY-P5351A Hyaluronan-binding peptide, biotin labeled TFA
Hyaluronan-binding peptide, biotin labeled TFA is a biological active peptide. (This peptide is a hyaluronan-binding peptide biotinylated through a C-terminal GGGSK linker. Hyaluronan (HA) is a nonsulfated glycosaminoglycan expressed in the extracellular matrix and on cell surfaces. HA plays a role in fertilization, embryonic development, wound healing, angiogenesis, leukocyte trafficking to inflamed tissues, and cancer metastasis. This peptide has been shown to block HA binding to CD44 receptors and inhibit T cell proliferation.).
/
HY-P5990 Prostate Specific Antigen Substrate
Prostate Specific Antigen Substrate is a highly specific fluorescent peptide substrate can be used for measuring prostate-specific antigen (PSA) enzymatic activity.
/
HY-172320 BMS-986238
BMS-986238 is an orally active macrocyclic peptide PD-L1 inhibitor. BMS-986238 can be used in the research of tumors such as solid tumors and lymphomas.
Cancer  
/
HY-P990061 Polzastobart
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antibody and LILRB2 (ILT4) antagonist. Polzastobart specifically binds to and antagonizes LILRB2, relieves ILT4-mediated myeloid immunosuppression, and promotes the polarization of macrophages from an M2-like phenotype to an M1-like phenotype. Polzastobart induces macrophage polarization, IFNγ signaling, and T cell inflammation-related pharmacodynamic responses in ex vivo human renal cancer, lung cancer, and head and neck cancer tissues. Polzastobart can be used in studies related to tumor-associated macrophages and tumor immunity. For the isotype control of Polzastobart, refer to: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

/
HY-P990759 Rezetamig
Rezetamig is a human bispecific antibody that recognizes the CD3 antigen on T-lymphocytes and the CD22 antigen on mature and malignant B-lymphocytes.

Species: Human

/
HY-W251598S Bicarbonate-13C sodium
Bicarbonate-13C sodium is the 13C-labeled Sodium bicarbonate (HY-Y0756). Sodium bicarbonate is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
/
HY-P990651 PY314
PY314 is a humanized antibody targeting TREM2. PY314 binds TREM2 on tumor-associated macrophages, depletes TREM2-high tumor-associated macrophages, reduces pro-tumorigenic M2 macrophage infiltration, increases CD8+ T cell, NK cell, and M1 macrophage infiltration, creates a proinflammatory tumor microenvironment, and promotes antitumor immune responseS. PY314 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, breast cancer, and advanced refractory solid tumors.

Species: Human

/
HY-N0594 Deacetylasperulosidic Acid
Deacetylasperulosidic Acid is an orally active antioxidant. Deacetylasperulosidic Acid exerts a definite in vivo antioxidant effect and alleviates oxidative stress injury by enhancing SOD activity. In atopic dermatitis models, Deacetylasperulosidic Acid corrects Th2-skewed immune imbalance and reduces allergy-related factors; in immunosuppression models, it activates cellular immunity, enhances NK cell activity and IL-2 production. Deacetylasperulosidic Acid can be used in the research of atopic dermatitis.
/
HY-P990042 Gotistobart
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer.

Species: Human

/
HY-P990650 PY159
PY159 is a humanized antibody targeting TREM1/CD354. PY159 reprograms immunosuppressive intratumoral myeloid cells towards an inflammatory, anti-tumor phenotype, promotes anti-tumor immune responses, upregulates monocyte activation markers, and induces proinflammatory cytokines. PY159 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, and advanced refractory solid tumors.

Species: Human

/
HY-P991739 RC148
RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 blocks PD-1-PD-L1 and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer.

Species: Human

/
HY-P0277 Carcinoembryonic antigen peptide 1
Carcinoembryonic antigen peptide 1 (CEA peptide) is a 9-amino acid HLA-A0201-binding cytotoxic T lymphocyte (CTL) epitope peptide derived from carcinoembryonic antigen (CEA). The IC50 of Carcinoembryonic antigen peptide 1 binding to HLA-A0201 is 2 μM. Carcinoembryonic antigen peptide 1 binds to HLA-A0201 to form a peptide-MHC I complex, which is recognized by the T cell receptor (TCR) of CAP1-specific CD8+ CTLs, thereby inducing antigen-specific T cell activation, IFN-γ production, and CTL-mediated lysis of target cells. Carcinoembryonic antigen peptide 1 is used in research on CEA-specific CTL responses and colorectal cancer.
/
HY-156712 Depatuxizumab MMAE
Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an anti EGFR monoclonal antibody (Depatuxizumab) (HY-P99849) and the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162). Depatuxizumab MMAE can be used for the study of EGFR-expressing advanced solid tumors.
/
HY-P99057 Varlilumab
Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors.

Species: Human

/
HY-D1831 Vari Fluor 620 TSA (200×)
Vari Fluor 620 TSA (200×) (VF 620 Tyramide) is a fluorescent probe belonging to the Vari Fluor TSA series. Vari Fluor TSA series fluorescent probes can be used for high-density in situ labeling of target antigens using horseradish peroxidase (HRP) assays, which are widely used in ELISA, IF, IHC and other techniques with high detection sensitivity.
/
HY-P10131 3BP-3940
3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases.
/
HY-P4116 pH-Low Insertion Peptide
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors.
/
HY-P99217 Rilotumumab
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.

Species: Human

/
HY-W251598B Sodium bicarbonate, for molecular biology
Sodium bicarbonate, for molecular biology (Sodium hydrogen carbonate for molecular biolog; Soda bicarbonate for molecular biolog) is an inorganic salt. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
/
HY-161553 Biotin/KLH
Biotin/KLH is an antigen-adjuvant conjugate that consists of Biotin and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
/
HY-N2424 Flavone
Flavone is an anti-tumor compound that targets cell cycle regulatory proteins (such as cyclin B1) and apoptosis-related factors (such as p21waf1, PIG3). Flavone selectively induces mitochondrial-mediated apoptosis pathways in tumor cells, inhibits cyclin B1 protein expression, upregulates p21waf1, and activates p63/p73 proteins. Flavone has immunomodulatory functions that enhance natural killer cell (NK cell) activity and lymphocyte proliferation. Flavone is used in cancer research, especially for its inhibitory potential in solid tumor models such as esophageal cancer and liver cancer.
/
HY-107202GL Polyinosinic-polycytidylic acid (GMP Like)
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
/
HY-P99401 Rosmantuzumab
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors.

Species: Human

Wnt  
Cancer  
/
HY-P99708 Livmoniplimab
Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors.

Species: Human

/
HY-P99118 Serplulimab
Serplulimab (HLX 10) is a humanized anti-PD-1 monoclonal antibody. Serplulimab can inhibit tumor growth, regulate the tumor microenvironment, and has anti-tumor activity. Serplulimab can be used in the research of cancer such as lung cancer and colon cancer.

Species: Human

/
HY-12489 Ponceau S
Ponceau S (Acid Red 112) is a non-specific protein dye commonly used as a stain for Western blot. Ponceau S is used in an acidic aqueous solution that is compatible with antibody-antigen binding and dyes the proteins on the membrane red.
/
HY-P99641 Gilvetmab
Gilvetmab is a canine-derived anti-cPD-1 monoclonal antibody, as well as an immune activator/antitumor agent. Gilvetmab binds to canine PD-1, blocks the interaction of PD-1/PD-L1/L2, prevents immunosuppression, reactivates antitumor responses, induces tumor regression or disease stabilization, and may also trigger pseudoprogression. Gilvetmab can be used in research related to malignant melanoma and mast cell tumors.

Species: Canine

/
HY-P99517 Voxalatamab
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer.

Species: Human

CD3   PSMA  
Cancer  
/
HY-171821 PF-08046054
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors
/
HY-177442 DS-3939a
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers.
/
HY-P6292A KS-133 TFA
KS-133 TFA is a highly selective and potent antagonist of the vascular active enteropeptide receptor 2 (VIPR2) with IC50 values for Ca influx measurement and cAMP measurement of 24.8 nM and 500 nM, respectively. KS-133 TFA reverses the tumor-promoting M2 phenotype of tumor-associated macrophages to the anti-tumor M1 phenotype, alters the tumor immune microenvironment, and inhibits tumor growth. KS-133 TFA can be used for research on schizophrenia and cancer immune regulation.
/
HY-177434 Precemtabart tocentecan
Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC.
/
HY-P99046 Selicrelumab
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study.

Species: Human

/
HY-W251598C Sodium bicarbonate, for cell culture
Sodium bicarbonate, for cell culture (Sodium hydrogen carbonate for cell culture; Soda bicarbonate for cell culture) is an inorganic salt that is neutral to slightly alkaline and easily decomposes when exposed to moisture in the air. Sodium bicarbonate, for cell culture can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, medicine, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
/
HY-P9918 Tremelimumab
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.

Species: Human

/
HY-108813 Belatacept
Belatacept (BMS 224818) is a selective T-cell costimulation blocker and a costimulator of the CD28-CD80/86 pathway. Belatacept binds to the CD 80/86 ligand and inhibits CD-28-mediated T cell costimulation and IFN-γ production. Belatacept can be used in studies of immunosuppression in organ transplantation. The component ratio of this product is Active ingredient : Excipients = 1:2.4.

Species: Human

/
HY-P71539 Lymphocyte antigen 6E/LY6E Protein, Human (His-SUMO)
Lymphocyte antigen 6E/LY6E protein is a GPI-anchored cell surface regulator that regulates T cell receptor signaling through interaction with CD3Z/CD247. It limits the entry of human coronaviruses, serves as the primary receptor for syncytin-A, and may modulate nicotinic acetylcholine receptor activity. Lymphocyte antigen 6E/LY6E Protein, Human (His-SUMO) is the recombinant human-derived Lymphocyte antigen 6E/LY6E protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

Species: Human; Source: E. coli

/
HY-P71830 Lymphocyte antigen 6E/LY6E Protein, Mouse (P.pastoris, His, SUMO)
LY6E is a GPI-anchored cell surface protein that regulates T lymphocyte function by binding to CD3Z/CD247, affecting proliferation, differentiation and activation.It modulates T cell receptor signaling and exhibits antiviral activity against mouse hepatitis virus.Lymphocyte antigen 6E/LY6E Protein, Mouse (P.pastoris, His, SUMO) is the recombinant mouse-derived Lymphocyte antigen 6E/LY6E protein, expressed by P.pastoris , with N-His, N-SUMO labeled tag.

Species: Mouse; Source: P. pastoris

/
HY-P75392 CD58 Protein, Human (HEK293, Fc)
CD58 Protein, Human (HEK293, Fc) is the recombinant human-derived CD58 protein, expressed by HEK293, with C-hFc labeled tag.

Species: Human; Source: HEK293

/
HY-P70217 Lymphocyte antigen 6H/LY6H Protein, Human (HEK293, His)
LY6H mediates the myelin trophic and neurotrophic effects of PSAP/Prosaposin protein through GPR37 and GPR37L1 receptors. Ligand-mediated internalization of these receptors results in ERK phosphorylation signaling. Lymphocyte antigen 6H/LY6H Protein, Human (HEK293, His) is the recombinant human-derived Lymphocyte antigen 6H/LY6H protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

/
HY-P76808 CD58 Protein, Cynomolgus (HEK293, His)
ANGPTL7/angiopoietin-related 7 protein plays a crucial role in the formation and organization of the extracellular matrix. Particularly in the eye, it serves as a mediator for dexamethasone-induced matrix deposition within the trabecular meshwork, a tissue that studies have shown is necessary for aqueous humor outflow and maintenance of intraocular pressure. CD58 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD58 protein, expressed by HEK293 , with C-His labeled tag.

Species: Cynomolgus; Source: HEK293

/
HY-P71803 26 kDa secreted antigen/TES-26 Protein, Canine (P.pastoris, His)
26 kDa secreted antigen/TES-26 Protein, Canine (P.pastoris, His) is a recombinant canine 26 kDa secreted antigen/TES-26 Protein expressed in P.pastoris with a His tag at the N-terminus. Recombinant TES-26 is a potential diagnostic candidate antigen for human toxocarosis caused by migrating T. canis larvae.

Species: Canine; Source: P. pastoris

/
HY-P702582 LY6D Protein, Human (HEK293, Fc)
LY6D Protein, Human (HEK293, Fc) is the recombinant human-derived LY6D, expressed by HEK293 , with C-mFc labeled tag. ,

Species: Human; Source: HEK293

/
HY-P705423 Lymphocyte antigen 6E/LY6E Protein, Human (HEK293, Fc)

Species: Human; Source: HEK293

/
HY-P705424 Lymphocyte antigen 6E/LY6E Protein, Mouse (HEK293, Fc)

Species: Mouse; Source: HEK293

/
HY-P80446 CD19 Antibody (YA543)
CD19 Antibody (YA543) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD19.

Host: Rabbit; Reactivity: Human

/
HY-P85091 CEA Antibody (YA4783)
CEA Antibody (YA4783) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CEA.

Host: Mouse; Reactivity: Human

/
HY-P81315 Anthrax Protective Antigen Antibody (YA1060)
Anthrax Protective Antigen Antibody (YA1060) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Anthrax Protective Antigen.

Host: Mouse; Reactivity: Bacillusanthracis

/
HY-P81315A Anthrax Protective Antigen Antibody (YA1060)(PBS only)
Anthrax Protective Antigen Antibody (YA1060) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Anthrax Protective Antigen.

Host: Mouse; Reactivity: Bacillusanthracis

/
HY-P81360 MAGEA1 Antibody (YA1105)
MAGEA1 Antibody (YA1105) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MAGEA1.

Host: Rabbit; Reactivity: Human

/
HY-P81360A MAGEA1 Antibody (YA1105)(PBS only)
MAGEA1 Antibody (YA1105) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MAGEA1.

Host: Rabbit; Reactivity: Human

/
HY-P81405 SAGE1 Antibody (YA1150)
SAGE1 Antibody (YA1150) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SAGE1.

Host: Rabbit; Reactivity: Human

/
HY-P81405A SAGE1 Antibody (YA1150)(PBS only)
SAGE1 Antibody (YA1150) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SAGE1.

Host: Rabbit; Reactivity: Human

/
HY-P85091A CEA Antibody (YA4783)(PBS only)
CEA Antibody (YA4783) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CEA.

Host: Mouse; Reactivity: Human

/
HY-P86647 CD19 Antibody (YA6339)
CD19 Antibody (YA6339) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD19.

Host: Rabbit; Reactivity: Human

/
HY-K0226 CHO Magnetic Beads (200 nm, 10 mg/mL)

MCE CHO Magnetic Beads (200 nm, 10 mg/mL) contain CHO functional groups, which react with primary amines on proteins or other molecules to form stable amide linkages,can covalently immobilize proteins for the affinity purification of antibodies, antigens and other biomolecules.

/
HY-K0227 NHS Magnetic Beads (200nm, 10 mg/mL)

MCE NHS Magnetic Beads (200 nm, 10 mg/mL) contain N-hydroxysuccinimide (NHS) functional groups, which react with primary amines on proteins or other molecules to form stable amide linkages,can covalently immobilize proteins for the affinity purification of antibodies, antigens and other biomolecules.

/
HY-K0354 Mouse CD3/CD28 T Cell Activation Magnetic Beads

MCE Mouse CD3/CD28 T Cell Activation Magnetic Beads are based on the two important co-stimulatory signals, without relying on feeder cells (antigen-presenting cells) or antigens, CD3 and CD28, without relying on feeder cells (antigen-presenting cells) or antigens, enabling simple and rapid T cell activation.

/
HY-K6141 Human Brain Organoid (Expansion) Kit

MCE Human Brain Organoid (Expansion) Kit contains Human Brain Organoid Expansion Basal Medium and Human Brain Organoid Expansion Culture Supplements. This kit enables the efficient in vitro generation of human forebrain organoids (hFBs). Within this culture system, human brain tissue can spontaneously form organoid structures that faithfully recapitulate key features of in vivo cellular heterogeneity and complex tissue organization.

/
HY-K6143 Mouse Fetal Brain Organoid (Expansion) Kit

MCE Mouse Fetal Brain Organoid (Expansion) Kit contains Mouse Fetal Brain Organoid Expansion Basal Medium and Mouse Fetal Brain Organoid Expansion Culture Supplement . This kit enables the efficient in vitro generation of mouse fetal brain organoids (mFBs). Within this culture system, mouse fetal brain tissue can spontaneously form organoid structures that faithfully recapitulate key features of in vivo cellular heterogeneity and complex tissue organization.

/
HY-KD1116 R-PE Rapid Labeling Kit
R-PE (R for phycoerythrin) is the brightest and most commonly used orange-red fluorescent protein probe in flow cytometry and immunofluorescence; it is particularly suitable for detecting low-expressing antigens. Excitation wavelengths: 488 nm (most common) and 561 nm; emission wavelength: 575 nm; flow cytometry channels: PE / 585/40 channels.
/

Keywords

solid tumors | CAR-T therapy | tumor microenvironment | T-cell trafficking | antigen heterogeneity | immunosuppression